Business Context and Reporting Period
This Form 8-K Current Report was filed by Compass Therapeutics, Inc. on December 9, 2024. The filing discloses significant changes to the company's executive leadership, specifically the appointment of a new Chief Financial Officer and Principal Accounting Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
- Appointment of CFO: Barry Shin was appointed Chief Financial Officer and Principal Financial Officer, effective December 9, 2024, replacing Thomas Schuetz (CEO) in the latter role.
- Appointment of Principal Accounting Officer: Neil Lerner, previously Vice President of Finance, was appointed Principal Accounting Officer, also replacing Thomas Schuetz.
- Compensation Structure: Mr. Shin's employment agreement includes a base salary of $475,000, a target bonus of 45%, a $50,000 sign-on bonus, and equity awards totaling 800,000 shares (400,000 options and 400,000 RSUs).
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of operational risks. It details severance provisions for Mr. Shin, including 9 months of base salary and COBRA coverage for standard terminations, and enhanced benefits (12 months of salary/bonus, COBRA, and full equity acceleration) in the event of a Change in Control.
Investor Verification Checklist
- Verify the vesting schedule for the 400,000 stock options and 400,000 RSUs granted to Barry Shin.
- Confirm the total potential cash compensation (salary + bonus) and the specific conditions for the $50,000 sign-on bonus.
- Review the definitions of "Cause" and "Good Reason" in the Employment Agreement (Exhibit 10.1) to understand severance triggers.
- Assess the impact of Thomas Schuetz stepping down as Principal Financial Officer and Principal Accounting Officer on internal financial controls.